A transdermal patch is a galenic form consisting of a reservoir with active substance that is released gradually while attached to the skin. Its goal is for the medicine to get in the blood flow through the skin surface and not the drug’s activity in the skin itself.
As we move forward in years, constantly we include more pharmaceuticals in our daily lives, and for this motive, the patches that attach to the skin get an essential importance to ward off problems due to a great consumption of pharmaceuticals, specially in the elderly age, and as well for your comfort.
Medicine-device combination inventions, like transdermal patch, introduced a new dynamic on medical product improvement, supervisory approval, and corporate cooperation that provide priceless lessons for the development of new types of combination solutions. Analysis indicate that the greatest obstacle to introduce a new type of combination products is the settlement of the supervisory center which would be to oversee its authorization, and also the device contract. The first invention of a recent kind of combination product gives a learning excuse for the regulator and the benefactor. As soon as the first product is ratified, the leading supervisory center is determined, and the confusion about the entire kind of combination solutions is utterly reduced.
The benefactor developing a new type of combination products undertakes a central role in diminishing this doubt by advising the decision on the most important objective of the combination product. This resolution affects the nature of the companies that will guide the introduction of these inventions into the market.